Science and Research

pro.LISA

Phase III trial testing FEV1 at age 5 years as the primary endpoint. Intervention group (prohylactic surfactant via LISA) vs. control group (rescue surfactant via LISA).

Study details
Study-ID: DRKS00028086
Study-ID: DRKS00028086
DZL Disease Area: PALI
DZL Disease Area: PALI
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL Investigator Initiated Trial
DZL Role: DZL Investigator Initiated Trial
Funding: Externally - public
Funding: Externally - public
DZL Participating Sites: ARCN
DZL Participating Sites: ARCN
Start Date: 05.03.2022
Completion Date: 31.03.2026
Status: Recruiting
Status: Recruiting
DZL Investigator Initiated Trial


chevron-down